Table 3 Seizure incidence and occurrence rates for all BRCA+ patients (adjusted for age at metastasis, number of prior lines of treatment, and metastasis location)
|  | N | N patients with a seizure | Median duration to seizure (days) | % patients with at least one seizure | Incidence person-years* | Incidence rate** (95% CI) | Total Occurrences | Occurrence frequency | Occurrence person-years†| Occurrence rate** |
|---|---|---|---|---|---|---|---|---|---|---|
Overall | 7941 | 2207 | 161 | 27.8% | 18655 | 7.28 (6.01–8.83) | 15,029 | 6.81 | 7468 | 201.26 |
Use of PARP inhibitors during evaluation period | ||||||||||
Patients exposed to PARP inhibitors | 92 | 16 | 53.5 | 17.4% | 61 | 76.58 (7.81–751.26) | 93 | 5.81 | 20 | 458.04 |
Patients not exposed to PARP inhibitors | 7849 | 2175 | 161 | 27.7% | 18452 | 7.20 (5.94–8.74) | 14827 | 6.82 | 7379 | 200.93 |
Diagnosed brain metastases during evaluation period | ||||||||||
Patients with diagnosed brain metastases | 1041 | 504 | 9 | 48.4% | 1002 | 42.55 (28.59–63.30) | 4071 | 8.08 | 951 | 428.06 |
Patients without diagnosed brain metastases | 6900 | 1627 | 153 | 23.6% | 16874 | 5.26 (4.20–6.59) | 9994 | 6.14 | 5796 | 172.43 |
History of seizures prior to index date | ||||||||||
Patients with history of seizures | 788 | 465 | 22 | 59.0% | 913 | 34.76 (23.24–52.01) | 5532 | 11.90 | 1336 | 414.12 |
Patients without history of seizures | 7153 | 1742 | 237.5 | 24.4% | 17743 | 6.35 (5.11–7.88) | 9497 | 5.45 | 6132 | 154.88 |
Use of anticonvulsants prior to index date | ||||||||||
Patients with history anticonvulsants | 2280 | 688 | 122.5 | 30.2% | 5057 | 7.6 (5.38–10.73) | 5956 | 8.66 | 2250 | 264.67 |
Patients without history of anticonvulsants | 5661 | 1519 | 178 | 26.8% | 13598 | 6.93 (5.50–8.75) | 9073 | 5.97 | 5217 | 173.91 |